| Year of Transplant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | ||
| Functioning Graft at Discharge | 34 | 33 | 21 | 22 | 17 | 35 | 29 | 24 | 29 | 21 | |
| With Immunosuppression Info | 33 | 33 | 21 | 22 | 17 | 35 | 29 | 24 | 28 | 20 | |
| Corticosteroids | Any in Category | 100.0% | 100.0% | 100.0% | 100.0% | 94.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Steroids | 100.0% | 100.0% | 100.0% | 100.0% | 94.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cyclosporine | Any in Category | 66.7% | 81.8% | 71.4% | 59.1% | 47.1% | 37.1% | 48.3% | 29.2% | 3.6% | 10.0% |
| Cyclosporin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 5.0% | |
| Sandimmmune | 18.2% | 6.1% | 9.5% | 13.6% | 5.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Neoral | 48.5% | 72.7% | 57.1% | 40.9% | 23.5% | 22.9% | 31.0% | 12.5% | 3.6% | 5.0% | |
| Gengraf | 0.0% | 3.0% | 4.8% | 4.5% | 17.6% | 14.3% | 13.8% | 16.7% | 0.0% | 0.0% | |
| Eon | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.4% | 0.0% | 0.0% | 0.0% | |
| Tacrolimus | Any in Category | 39.4% | 27.3% | 23.8% | 45.5% | 52.9% | 65.7% | 55.2% | 75.0% | 96.4% | 90.0% |
| Tacrolimus | 39.4% | 27.3% | 23.8% | 45.5% | 52.9% | 65.7% | 55.2% | 75.0% | 96.4% | 90.0% | |
| Antimetabolites | Any in Category | 84.8% | 93.9% | 95.2% | 95.5% | 82.4% | 82.9% | 96.6% | 91.7% | 85.7% | 95.0% |
| Mycophenolate Mofetil | 48.5% | 45.5% | 52.4% | 40.9% | 29.4% | 54.3% | 55.2% | 70.8% | 67.9% | 85.0% | |
| Mycophenolate Sodium | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 3.6% | 5.0% | |
| Azathioprine | 36.4% | 48.5% | 42.9% | 54.5% | 52.9% | 28.6% | 41.4% | 20.8% | 14.3% | 5.0% | |
| mTOR Inhibitors | Any in Category | 0.0% | 0.0% | 0.0% | 0.0% | 5.9% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sirolimus | 0.0% | 0.0% | 0.0% | 0.0% | 5.9% | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Everolimus | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |